Recurring concern
Failure to provide timely clinical follow-up after medication prescribing
First reported 14 Aug 2013•Latest report 6 Jan 2026
What this concern includes
Includes timely clinical review after prescribing, assessment of treatment response, adherence or collection monitoring, and escalation when follow-up identifies concern.
Not included
- Unsafe prescribing, dispensing or administration where no follow-up deficiency is identified
- Generic appointment failures unrelated to prescribed medication
- Medication-specific toxicity or blood-level monitoring governed by a narrower dedicated control
- Reports
- 21
- Individual concerns
- 23
- Date range
- 2013–2026
- Stated actions
- 35
Distinct published reports
A report can raise multiple concerns
First to latest report issue date
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
-
Concerns raised2
Failure to complete PHQ9 assessments after antidepressant prescribing
Failure to provide timely follow-up after antidepressant prescribing
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
Data last updated 7 September 2026